Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Robin Jean Bell; Max Allan Schwarz; Pam Fradkin; Penelope Jane Robinson; Susan Ruth Davis

doi:10.1097/GME.0b013e31827ce094

Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Robin Jean Bell, Max Allan Schwarz, Pam Fradkin, Penelope Jane Robinson, Susan Ruth Davis

Research output: Contribution to journal › Article › Research › peer-review

8 Citations (Scopus)

Abstract

Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.

Original language	English
Pages (from-to)	721 - 726
Number of pages	6
Journal	Menopause
Volume	20
Issue number	7
DOIs	https://doi.org/10.1097/GME.0b013e31827ce094
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/GME.0b013e31827ce094

Cite this

@article{bf2744e993ac4892bcb7b526dc7d9195,

title = "Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis",

abstract = "Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.",

author = "Bell, {Robin Jean} and Schwarz, {Max Allan} and Pam Fradkin and Robinson, {Penelope Jane} and Davis, {Susan Ruth}",

year = "2013",

doi = "10.1097/GME.0b013e31827ce094",

language = "English",

volume = "20",

pages = "721 -- 726",

journal = "Menopause",

issn = "1072-3714",

publisher = "Lippincott Williams & Wilkins",

number = "7",

}

TY - JOUR

T1 - Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

AU - Bell, Robin Jean

AU - Schwarz, Max Allan

AU - Fradkin, Pam

AU - Robinson, Penelope Jane

AU - Davis, Susan Ruth

PY - 2013

Y1 - 2013

N2 - Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.

AB - Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23793165

U2 - 10.1097/GME.0b013e31827ce094

DO - 10.1097/GME.0b013e31827ce094

M3 - Article

SN - 1072-3714

VL - 20

SP - 721

EP - 726

JO - Menopause

JF - Menopause

IS - 7

ER -

Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Abstract

UN SDGs

Access to Document

Other files and links

The Clinical Centre of Research Excellence: for the study of women's health

Cite this

Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Abstract

UN SDGs

Access to Document

Other files and links

Projects

The Clinical Centre of Research Excellence: for the study of women's health

Cite this